Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic iNKT Cell Infusion in Advanced Pancreatic Cancer
NCT07055568Phase 1Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Allogeneic CAR-T, Lymphokine-Activated Killer Cells, Autologous CAR-T
01
Overview
Phase 1, open-label, single-arm trial of agenT-797 in pancreatic cancer (PC), sponsored by Shanghai General Hospital. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
agenT-797
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07055568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055568.